The biotech company american Inovio announced Tuesday the preliminary results are encouraging for the design of vaccine against the new coronavirus, which is administered on 40 volunteers in the United States.
Read also A vaccine against the coronavirus tested in Africa
According to a company release, the vaccine caused an immune system response in 94 % of the participants who have completed the clinical trial, called phase 1, until the end, that is to say, with two injections four weeks apart.